In this episode, the pulmonologists participating in a roundtable discussion go beyond the challenges of pulmonary nodule management to discuss how CyPath® Lung is being integrated into real-world clinical workflows. The panel explores patient anxiety and stigma, when to biopsy and when not to, and how a noninvasive sputum-based test can risk stratify and help guide next steps for patients with indeterminate pulmonary nodules.

The discussion also takes a deeper look at the science behind CyPath® Lung and offers compelling patient cases—including a smoker ultimately diagnosed with Stage I lung cancer and a heart transplant candidate with a difficult-to-access pulmonary nodule.

A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer.

Moderator: Gordon Downie, MD, PhD bioAffinity Technologies Chief Medical Officer

Panelists:

· Sai Karan Vamsi Guda, DO Interventional pulmonologist with Texas Pulmonary & Critical Care Consultants

· Michael Nicholson, DO Pulmonologist and critical care specialist with RWJBarnabas Health Medical Group

· Gregory White, MD Pulmonologist at CHRISTUS Trinity Clinic